ANIP

ANI Pharmaceuticals, Inc. NASDAQ

Healthcare ·Drug Manufacturers - Specialty & Generic ·US · anipharmaceuticals.com

$84.63

Mkt Cap $1.9B

52w Low $56.71 65.2% of range 52w High $99.50

50d MA $76.58 200d MA $82.75

P/E (TTM) 23.0x

EV/EBITDA 7.8x

P/B 3.0x

Debt/Equity 0.6x

ROE 14.5%

P/FCF 9.2x

RSI (14) —

ATR (14) —

Beta 0.43

50d MA $76.58

200d MA $82.75

Avg Volume 360.0K

About

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent pr…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 27, 2026	AMC	1.99	2.33	+17.1%	73.90	+0.1%	+1.8%	+3.0%	+3.6%	+2.3%	+0.2%	—
Nov 7, 2025	AMC	1.74	2.04	+17.2%	90.43	-3.2%	-1.7%	-2.1%	-3.5%	-6.5%	-7.1%	—
Aug 8, 2025	AMC	1.38	1.80	+30.4%	81.48	+0.0%	+4.2%	+8.4%	+8.9%	+10.5%	+7.4%	—
May 9, 2025	AMC	1.37	1.70	+24.1%	66.30	-0.0%	-6.0%	-6.5%	-8.9%	-10.2%	-9.5%	—
Feb 28, 2025	AMC	1.41	1.63	+15.6%	61.89	-1.6%	-5.5%	-4.5%	-3.6%	-1.4%	-2.1%	—
Nov 8, 2024	AMC	1.09	1.34	+22.9%	61.44	+0.1%	+0.5%	-0.7%	-2.6%	-4.1%	-7.9%	—
Aug 6, 2024	AMC	0.93	1.02	+9.7%	63.29	-15.5%	-9.9%	-10.8%	-8.5%	-5.7%	-6.9%	—
May 10, 2024	AMC	0.98	1.21	+23.5%	68.05	-0.5%	-1.0%	-3.0%	-4.7%	-6.3%	-9.7%	—
Feb 29, 2024	AMC	0.80	1.00	+25.0%	67.67	+0.8%	-0.7%	-1.8%	-3.4%	-2.7%	-1.4%	—
Nov 8, 2023	AMC	0.76	1.27	+67.1%	54.32	+1.2%	-3.8%	-4.0%	-4.9%	-2.0%	-3.7%	—
Aug 9, 2023	AMC	0.64	1.28	+100.0%	61.08	+1.2%	-0.8%	+2.6%	+0.0%	+1.3%	-2.8%	—
May 8, 2023	AMC	0.34	1.17	+244.1%	42.58	+2.9%	+4.3%	+2.8%	+3.2%	-2.1%	-4.0%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Jan 16	Guggenheim	Maintains	Buy → Buy	—	$85.29	$85.92	+0.7%	-0.5%	+0.6%	+0.3%	+0.1%	-2.7%
Nov 10	Guggenheim	Maintains	Buy → Buy	—	$90.43	$87.58	-3.2%	-1.7%	-2.1%	-3.5%	-6.5%	-7.1%
Oct 9	Truist	Maintains	Hold → Hold	—	$91.65	$91.65	+0.0%	-0.9%	-2.0%	-3.3%	-3.2%	-1.7%
Sep 24	JP Morgan	Maintains	Overweight → Overweight	—	$95.33	$96.41	+1.1%	-0.4%	-2.1%	-2.4%	-3.6%	-3.9%
Sep 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$97.55	$98.18	+0.6%	-2.2%	-0.1%	-0.8%	-1.7%	-2.3%
Sep 8	Guggenheim	Maintains	Buy → Buy	—	$95.35	$95.85	+0.5%	-0.2%	+3.3%	+2.2%	+3.5%	+2.5%
Aug 11	Truist	Maintains	Hold → Hold	—	$81.48	$81.50	+0.0%	+4.2%	+8.4%	+8.9%	+10.5%	+7.4%
Aug 8	HC Wainwright & Co.	Maintains	Buy → Buy	—	$69.01	$77.86	+12.8%	+18.1%	+23.0%	+28.0%	+28.6%	+30.4%
May 12	Guggenheim	Maintains	Buy → Buy	—	$66.30	$66.28	-0.0%	-6.0%	-6.5%	-8.9%	-10.2%	-9.5%
Apr 21	Truist	Maintains	Hold → Hold	—	$69.21	$69.16	-0.1%	-1.7%	-0.4%	-1.2%	+0.6%	+0.9%
Apr 11	Guggenheim	Maintains	Buy → Buy	—	$65.12	$65.45	+0.5%	+4.6%	+5.5%	+6.8%	+6.3%	+6.3%
Mar 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$62.49	$62.81	+0.5%	+3.0%	+2.8%	+3.8%	+3.0%	+2.8%
Mar 5	Guggenheim	Maintains	Buy → Buy	—	$59.13	$59.14	+0.0%	+0.9%	+3.2%	+2.5%	-0.5%	+3.8%
Mar 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$61.89	$60.89	-1.6%	-5.5%	-4.5%	-3.6%	-1.4%	-2.1%
Nov 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$61.44	$61.53	+0.1%	+0.5%	-0.7%	-2.6%	-4.1%	-7.9%
Oct 22	Truist	Maintains	Hold → Hold	—	$59.28	$58.95	-0.6%	+1.3%	-0.4%	+0.0%	-1.6%	-2.2%
Sep 18	Raymond James	Maintains	Outperform → Outperform	—	$60.06	$60.46	+0.7%	+1.6%	+0.5%	-0.7%	+0.0%	-2.6%
Sep 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$56.20	$57.05	+1.5%	+6.9%	+8.6%	+7.4%	+6.2%	+6.9%
Sep 11	Truist	Downgrade	Buy → Hold	—	$55.48	$53.51	-3.6%	-2.1%	+1.2%	+5.5%	+1.3%	+8.3%
Aug 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$63.29	$53.51	-15.5%	-9.9%	-10.8%	-8.5%	-5.7%	-6.9%
Jun 26	HC Wainwright & Co.	Maintains	Buy → Buy	—	$64.19	$65.29	+1.7%	+2.0%	-1.7%	-0.8%	-1.2%	-2.4%
May 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$68.05	$67.69	-0.5%	-1.0%	-3.0%	-4.7%	-6.3%	-9.7%
Apr 23	Guggenheim	Maintains	Buy → Buy	—	$65.62	$65.90	+0.4%	+0.8%	-0.3%	-1.0%	-0.4%	-0.2%
Mar 5	Guggenheim	Maintains	Buy → Buy	—	$66.42	$66.59	+0.3%	-1.6%	-0.9%	+0.4%	+1.5%	-0.4%
Mar 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$67.17	$67.00	-0.3%	-1.1%	-2.7%	-2.0%	-0.7%	+0.4%
Mar 1	Truist	Maintains	Buy → Buy	—	$67.67	$68.24	+0.8%	-0.7%	-1.8%	-3.4%	-2.7%	-1.4%
Feb 16	Truist	Maintains	Buy → Buy	—	$57.55	$57.98	+0.7%	+3.8%	+1.4%	+0.1%	+1.0%	+2.7%
Oct 19	Guggenheim	Maintains	Buy → Buy	—	$57.39	$57.21	-0.3%	-0.1%	+0.1%	-0.9%	+1.2%	+2.8%
Sep 13	Guggenheim	Maintains	Buy → Buy	—	$61.91	$61.97	+0.1%	+1.5%	+2.7%	+0.8%	-0.8%	-1.3%
Aug 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$61.21	$61.59	+0.6%	+2.1%	+4.2%	+3.5%	+4.2%	+2.5%
Aug 21	Truist	Maintains	Buy → Buy	—	$59.69	$58.90	-1.3%	+2.5%	+4.7%	+6.9%	+6.1%	+6.9%
Aug 10	Guggenheim	Maintains	Buy → Buy	—	$61.08	$61.83	+1.2%	-0.8%	+2.6%	+0.0%	+1.3%	-2.8%
Jul 27	Guggenheim	Maintains	Buy → Buy	—	$52.19	$52.57	+0.7%	-1.2%	+0.3%	+0.7%	-2.7%	-2.0%
Jul 21	Truist	Maintains	Buy → Buy	—	$51.68	$52.10	+0.8%	+1.0%	+2.1%	+2.1%	+1.0%	-0.3%
May 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$42.58	$43.83	+2.9%	+4.3%	+2.8%	+3.2%	-2.1%	-4.0%
May 9	Truist	Maintains	Buy → Buy	—	$42.58	$43.83	+2.9%	+4.3%	+2.8%	+3.2%	-2.1%	-4.0%
May 9	Raymond James	Maintains	Outperform → Outperform	—	$42.58	$43.83	+2.9%	+4.3%	+2.8%	+3.2%	-2.1%	-4.0%
May 9	Guggenheim	Maintains	Buy → Buy	—	$42.58	$43.83	+2.9%	+4.3%	+2.8%	+3.2%	-2.1%	-4.0%
Mar 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$40.86	$40.84	-0.0%	+0.4%	-0.8%	-2.1%	-2.7%	-3.7%
Mar 1	Guggenheim	Maintains	Buy → Buy	—	$41.84	$43.18	+3.2%	+4.7%	+6.1%	+8.7%	+6.2%	+5.7%
Feb 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$43.08	$43.08	+0.0%	-6.6%	-4.8%	-4.3%	-4.5%	-2.9%
Sep 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$34.94	$35.45	+1.5%	+6.3%	+7.6%	+6.2%	+4.2%	+3.2%
Aug 9	Raymond James	Maintains	Outperform → Outperform	—	$34.87	$34.98	+0.3%	-2.5%	+0.3%	+1.5%	+7.5%	+8.5%
Mar 16	Raymond James	Maintains	Outperform → Outperform	—	$29.01	$28.06	-3.3%	-7.3%	-2.4%	-6.1%	-7.2%	-5.3%
Nov 2	Truist	Maintains	Buy → Buy	—	$55.89	$55.42	-0.8%	+1.7%	+1.4%	-10.5%	-10.5%	-10.4%
Nov 2	Raymond James	Maintains	Outperform → Outperform	—	$55.89	$55.42	-0.8%	+1.7%	+1.4%	-10.5%	-10.5%	-10.4%
May 10	Raymond James	Maintains	Outperform → Outperform	—	$38.60	$39.23	+1.6%	-14.8%	-13.9%	-13.1%	-13.1%	-9.2%
Aug 3	Raymond James	Maintains	Outperform → Outperform	—	$29.61	$29.56	-0.2%	+0.8%	+4.2%	+4.7%	-0.4%	+2.6%
May 8	Raymond James	Maintains	Outperform → Outperform	—	$34.06	$33.98	-0.2%	+0.9%	+2.2%	-4.6%	-8.5%	-11.2%
May 7	Cantor Fitzgerald	Downgrade	Overweight → Neutral	—	$36.96	$40.62	+9.9%	-7.8%	-7.0%	-5.8%	-12.1%	-15.7%

Recent Filings

8-K · 4.01 !!! Very High

Unknown — 8-K 4.01: Auditor Change / Resignation

ANIP's auditor switch from EisnerAmper to Ernst & Young suggests potential cost optimization or growth, but investors should verify if any audit disagreements prompted the change, which could signal hidden financial issues.

Apr 7

8-K · 7.01 ! Medium

ANI Pharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure

ANI Pharmaceuticals updated its investor presentation for use in ongoing investor and analyst meetings, providing stakeholders with current company information and financial guidance.

Mar 3

8-K

ANI Pharmaceuticals, Inc. -- 8-K Filing

ANI Pharmaceuticals reported strong Q4 2025 results and is strategically pivoting toward rare disease focus while maintaining its generics business, positioning for accelerated growth in 2026.

Feb 27

Data updated apr 24, 2026 6:11pm · Source: massive.com